Bowel Stimulators Market

On 15 November 2024 Boston Scientific closed its purchase of Axonics for about USD 3.7 billion, buying a rechargeable sacral neuromodulation system approved by the US Food and Drug Administration for faecal incontinence in 2019 and putting two of the largest medical device companies head to head in bowel stimulation. Douglas Insights values the bowel stimulators market at USD 402.0 million in 2025 and forecasts USD 915.2 million by 2035, a compound growth rate of 8.57%. The receipt is about 60,000 bowel stimulation therapy starts worldwide in 2025 at an average device value of USD 6,700, across sacral neuromodulation implants, tibial nerve stimulation, vibrating capsules and transcutaneous and anal electrical stimulation. Therapy starts grow 7.5% a year as colorectal surgeons refer more patients and new non-surgical devices reach constipation, while value per start rises 1.0% a year as rechargeable and longer-lasting implants take share. The report sits within Douglas Insights coverage of medical devices and follows the published Douglas Insights methodology.

What are bowel stimulators, and what does the market include?

Bowel stimulators are medical devices that use electrical pulses or mechanical vibration to improve bowel control or movement, and about 60,000 patients started such therapy in 2025. Sacral neuromodulation places a thin lead next to the sacral nerves at the base of the spine, connected to a small implanted pulse generator, and is used mainly for faecal incontinence. Tibial nerve stimulation reaches the same nerve roots through a needle or electrode near the ankle in weekly clinic sessions. Vibrating capsules are swallowed and vibrate inside the colon to trigger contractions in chronic constipation. Transcutaneous and anal electrical stimulation uses skin or anal electrodes, often with biofeedback, for incontinence and constipation in adults and children. The market counts device revenue at manufacturer realised price, including trial leads, implants, programmers and capsules. Surgeon and hospital fees, drugs for constipation, pads and other containment products, and sacral neuromodulation used for bladder conditions sit outside the boundary.

What did Boston Scientific’s Axonics deal change for bowel stimulators?

Boston Scientific’s Axonics deal turned bowel stimulators from a Medtronic-led niche into a two-major contest backed by a USD 3.7 billion bet on sacral neuromodulation. Medtronic’s InterStim was approved for faecal incontinence in the United States in March 2011, and for a decade it had the field almost to itself. Axonics entered with a rechargeable implant in 2019 and later a recharge-free model, and by 2023 had become the second supplier. Under Boston Scientific, which already sells spinal cord stimulators and has a large pelvic health sales force, Axonics gains reach in Europe and Asia. Douglas Insights estimates sacral neuromodulation holds 70% of 2025 bowel stimulator value, USD 281.4 million, growing 7.43% a year to USD 576.1 million by 2035, with competition lifting surgeon training and referral more than it cuts prices.

How many people could use a bowel stimulator?

About 8% of adults report faecal incontinence and about 14% report chronic constipation, so hundreds of millions of people have bowel symptoms that a bowel stimulator might one day treat. Most are managed with diet, drugs, pelvic floor exercises and pads, and only those who fail these steps are referred for device therapy. Douglas Insights estimates that about 2% of adults with severe faecal incontinence that does not respond to conservative care receive sacral neuromodulation in the United States, and under 1% in Europe and Asia. Of the 60,000 bowel stimulation therapy starts in 2025, about 60% were for faecal incontinence and 40% for constipation, and the constipation share rises to about 50% by 2035 as capsules spread.

What drives bowel stimulator demand?

Referral growth is the first driver. Colorectal surgeons, gastroenterologists and pelvic floor clinics increasingly follow a stepped pathway that ends in sacral neuromodulation for faecal incontinence, and Douglas Insights estimates the number of centres implanting bowel stimulators in the United States and Europe rose by about 30% between 2020 and 2025. Therapy starts grow 7.5% a year, from about 60,000 in 2025 to about 124,000 in 2035, as more centres train surgeons and patients learn that incontinence is treatable. Douglas Insights estimates about 10,000 sacral neuromodulation implants for bowel indications were placed in the United States in 2025, up from about 7,000 in 2020, and a newly trained surgeon typically adds 10 to 30 cases a year.

Better implants are the second driver. Rechargeable and recharge-free sacral neuromodulation implants last 10 to 15 years or more, against about 5 years for older non-rechargeable devices, and are compatible with full-body MRI scans, which removes a common reason patients declined therapy. Longer-lived implants also carry higher prices, supporting the 1.0% annual rise in average device value to about USD 7,400 by 2035.

New constipation devices are the third driver. The Vibrant capsule received FDA marketing authorisation in August 2022 for adults with chronic idiopathic constipation who have not responded to laxatives, and in its main Phase 3 trial about 39% of patients on the capsule reached the main response goal against about 22% on sham. Vibrating capsules hold 6% of 2025 bowel stimulator value, USD 24.1 million, and are the fastest-growing segment at 21.35% a year, reaching USD 167.1 million by 2035. The capsule is taken five days a week and needs no surgery, so gastroenterologists can offer a device without referring patients to a surgeon.

Ageing and childbirth injury are the fourth driver. Faecal incontinence rises with age and after obstetric sphincter injury, which affects about 3% of vaginal births in the UK, and the number of people aged 65 and over worldwide grows by about 3% a year to 2035, adding about 1.5 points a year to bowel stimulator therapy starts. Pelvic floor services for women after childbirth, expanding in the UK, France and Australia, bring younger patients into the pathway earlier.

What holds back the bowel stimulators market?

Three restraints cut the 2035 bowel stimulators figure to about USD 593.8 million in the slower case. Cost and reimbursement come first: a sacral neuromodulation implant costs USD 15,000 to USD 25,000 for the device alone, and many health systems outside the United States fund only a limited number of procedures a year, so waiting lists run 6 to 18 months in parts of Europe.

Evidence gaps come second: sacral neuromodulation helps about 70% to 80% of implanted faecal incontinence patients, but the UK CONFIDeNT trial found percutaneous tibial nerve stimulation no better than sham for faecal incontinence, which holds tibial nerve stimulation to 8% of value and slow growth of 6.93% a year. Stigma and low awareness come third: many patients never tell a doctor about incontinence, and Douglas Insights estimates fewer than 1 in 5 people with severe symptoms have discussed treatment options with a specialist. Lead migration, pain at the implant site and revision surgery in about 10% to 20% of patients over 5 years also make some surgeons cautious.

Which bowel stimulator segments carry the most value?

Sacral neuromodulation leads with 70% of 2025 value. These bowel stimulators earned USD 281.4 million, growing 7.43% a year, because implants are expensive and are the best-proven device for faecal incontinence. Transcutaneous and anal electrical stimulation holds 16%, USD 64.3 million, and grows slowest at 5.44% a year, since low-cost home units compete on price. Tibial nerve stimulation holds 8%, USD 32.2 million, growing 6.93% a year on mixed evidence. Vibrating capsules hold 6%, USD 24.1 million, and are the fastest-growing segment at 21.35% a year as the first drug-free device option for chronic constipation reaches more US patients.

By indication, Douglas Insights estimates faecal incontinence took about 75% of 2025 value and chronic constipation about 25%. By care setting, hospitals took about 70% of value, ambulatory surgery centres about 20% and home use about 10%.

Which regions buy the most bowel stimulators, and which grows fastest?

North America buys the most, 58% of 2025 value, and Asia Pacific is the fastest-growing region at 12.32% a year. North American bowel stimulator sales reached USD 233.2 million in 2025, growing 7.83% a year to USD 495.3 million, because Medicare and private insurers cover sacral neuromodulation for faecal incontinence and the Vibrant capsule launched there first. Europe holds 28%, USD 112.6 million, growing 8.32% a year, led by Germany, the UK, France, Italy and the Netherlands, where NICE and national colorectal societies have supported sacral nerve stimulation since the 2000s. Asia Pacific holds 10%, USD 40.2 million, rising to USD 128.5 million by 2035 as Japan, Australia, China and South Korea add implanting centres. Latin America adds USD 10.1 million and the Middle East and Africa USD 6.0 million, both growing 9.82% a year from small private-hospital bases.

Which companies make bowel stimulators?

Bowel stimulators are concentrated: Douglas Insights estimates Medtronic holds about 45% of 2025 value and Medtronic and Boston Scientific together about 67%. Medtronic sells the InterStim family, including rechargeable and recharge-free implants, and has the largest base of trained implanting surgeons. Boston Scientific sells the Axonics system, bought in November 2024, with rechargeable and recharge-free implants that last 15 years or more. Vibrant Gastro makes the Vibrant vibrating capsule for chronic constipation. Laborie sells the Urgent PC tibial nerve stimulation system, and The Prometheus Group and other pelvic floor device makers supply biofeedback and anal electrical stimulation units. Companies win on implant longevity, MRI compatibility, surgeon training and reimbursement support. Wider neuromodulation for pain is sized in our Pain Management Devices Market report.

How much does a bowel stimulator cost?

A bowel stimulator cost an average USD 6,700 per therapy start in 2025, across a very wide range. A sacral neuromodulation system, including trial leads, implant and programmer, sells for about USD 15,000 to USD 25,000 in the United States and about 30% less in Europe, and the full procedure with hospital fees costs roughly twice the device price. A course of 12 weekly tibial nerve stimulation sessions uses disposable needle leads worth a few hundred dollars. The Vibrant capsule is prescribed as a course of capsules costing several hundred dollars a month where it is sold. Transcutaneous and anal stimulation units for home use cost USD 100 to USD 800. Douglas Insights expects the average value per start to rise to about USD 6,770 in 2026 and USD 7,400 in 2035 as longer-lasting implants take share, partly offset by more low-cost capsule and home-unit starts.

How could the bowel stimulators forecast change by 2035?

The bowel stimulators forecast ranges from USD 593.8 million to USD 1.33 billion in 2035. The base case carries 7.5% growth in therapy starts and 1.0% growth in value per start, for an 8.57% revenue CAGR and USD 915.2 million. The slower scenario, with tight hospital budgets, slow capsule uptake and price pressure after the Axonics deal, sets the legs at 4.5% and −0.5%, for 3.98% growth. The faster scenario, with Boston Scientific and Medtronic expanding training in Asia and payers covering capsules widely, sets them at 10.0% and 2.5%, for 12.75% growth. Each 1-point change in therapy-start growth moves the 2035 figure by about USD 88.8 million. Skin-friendly adhesives used on external electrodes are sized in our Medical Adhesive Transfer Tapes Market report.

Douglas Exclusive: the bowel neuromodulation referral and reimbursement tracker

The Douglas Exclusive tracker counts implanting centres, trained surgeons and bowel stimulator procedure volumes in 15 countries, and records reimbursement status and tariff for sacral neuromodulation, tibial nerve stimulation and vibrating capsules in each. Licence holders receive it as a maintained tab in the Excel model, updated as Medtronic and Boston Scientific expand training and as payers decide on capsule coverage.

Which regulations shape the bowel stimulators market?

Three layers of rules shape the bowel stimulators market, starting with the FDA approvals behind the two sacral neuromodulation systems. Device approval comes first: in the United States sacral neuromodulation implants need premarket approval, while the Vibrant capsule reached market through the De Novo route in August 2022; in Europe the Medical Device Regulation (EU) 2017/745 treats active implants as class III devices that need notified-body review and clinical evidence. Reimbursement comes second: Medicare coverage of sacral neuromodulation for faecal incontinence, national tariffs in Europe and hospital budgets decide how many procedures are funded. Clinical guidelines come third: colorectal and gastroenterology societies place sacral neuromodulation after conservative care and before major surgery, which sets the referral pathway.

What methodology sits behind the bowel stimulators model?

The bowel stimulators model is built bottom-up from about 60,000 therapy starts in 2025 at an average USD 6,700 each. It covers 4 device segments, 2 indications, 3 care settings and 5 regions. Starts come from procedure and prescription data in 20 countries, company disclosures on implant volumes, and implanting centre counts; prices come from hospital purchasing data, reimbursement tariffs and company reports. Surgeon and hospital fees, drugs and containment products, and sacral neuromodulation for bladder indications are excluded, and growth is decomposed as therapy starts times value per start. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.

Sources

1. Boston Scientific Boston Scientific Closes Acquisition of Axonics, Inc. (2024)
2. EUR-Lex Regulation (EU) 2017/745 on medical devices (2017)